Navigation Links
Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
Date:4/5/2013

Florida 33137.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the Company's securities.  No offer, solicitation, or sale will be made in any jurisdiction in which such offer, solicitation, or sale is unlawful.  The terms and conditions of the transactions described in this press release are qualified in their entirety by reference to the transaction documents, which will be filed with the SEC on Form 8-K.

With respect to exchange listing compliance, on April 4, 2013, we received a communication from the NYSE MKT, the company's current exchange, indicating that the exchange had determined that in accordance with section 1009 of the exchange's company guide, we had made a reasonable demonstration of our ability to regain compliance with Section 1003(a)(iv) of the company guide by the end of a revised plan period which was determined to be June 30, 2013. The company will continue to be subject to periodic review by the exchange staff during the period covered by the plan.  Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the applicable extension periods could result in the company's shares being delisted from the exchange. If the company's common stock was not traded on the NYSE MKT, it would be expected to trade on the OTCQX, an alternative regulated quotation service that provides quotes, sale prices and volume information in over-the-counter equity securities.  The company's common stock was traded on the OTC until July 2007, when the company elected to instead list its shares on the American Stock Exchange.    

About Cardium         

Cardium is an asset-based health sciences and regenerative medicine company focused on the acquisition and strategic development of innovative products and businesses with the
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium Receives ISO Certification for Excellagen
2. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
3. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
4. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
5. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
6. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
7. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
10. MEI Pharma Announces $15.2 Million Registered Offering Of Common Stock
11. EntreMed Announces Changes to Board of Directors and CEO Appointment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)...  The Healthcare Analytics Summit 2014 (HAS ... Salt Lake City , Sept. 24-25 has added ... organizations in the U.S. and beyond.  HAS ,14, powered ... devoted to providing immersive learning experiences on the ... accountable care initiatives and population health managemen t ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 ... antivirals has amplified with rising incidence rates and ... absence of a preventative vaccine. Change is underway ... and interferon regimens towards highly effective, easily-tolerated, interferon-free ... http://photos.prnewswire.com/prnh/20140728/130662 Gilead,s mega blockbuster ...
(Date:7/29/2014)... LONDON , July 29, 2014 ... 2014 Global Frost & Sullivan Best Practices Award ... solution is a cloud-based platform that connects digital ... - such as providers, pharmaceutical companies, prevention and ... electronics. Each year, Frost & ...
Breaking Medicine Technology:Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 2Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 3Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 4Health Catalyst Adds Keynote Speakers, New Sessions, and Expands Attendee Limit for Healthcare Analytics Summit 2014 5A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 2Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 3Frost & Sullivan Commends Validic for Delivering Superior Customer Value through its mHealth Interoperability Technology Platform 4
... ZURICH , July 19, 2010 Today, Novo Nordisk ... designed to investigate the effects of modern insulins in,the management of type 2 diabetes.[1] ... Spanning 28 countries across ... largest observational study,in insulin therapy. , , ...
... July 16 Human erythropoietin (EPO) is a ... and spinal cord injury, and Parkinson,s disease. However, EPO drug ... cross the blood-brain barrier (BBB). In acute stroke or brain ... the insult when neuroprotection is still possible. Therefore, large molecule ...
Cached Medicine Technology:World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 2World's Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients 3ArmaGen® Re-engineers Erythropoietin for Brain Penetration 2
(Date:7/29/2014)... NJ (PRWEB) July 29, 2014 ... free of blood and protein soils where it ... Miele, the world’s leading manufacturer of premium domestic ... to verifying surgical instruments are effectively cleaned. The ... of surgical instruments immediately after processing. After 3 ...
(Date:7/29/2014)... is in principle suitable to find out which preferences ... it in health economic evaluations, some (primarily methodological) issues ... of a pilot project by the German Institute for ... Analytic Hierarchy Process (AHP), CA is the second method ... Summarize outcome-specific results to an overall value ...
(Date:7/29/2014)... new lung is grown for a patient in need, using ... injection of replacement cells will enable a patient to self-heal ... ALERT: For audio and video of Dr. Keller and Jorge ... Mayo Clinic News Network . , Regenerative ... gift from Jorge and Leslie Bacardi of the Bahamas will ...
(Date:7/29/2014)... Foot Levelers Chairman and CEO Kent S. Greenawalt ... (FCA) National Convention and Expo, speaking on Ground Force ... on Thursday, August 20th at the Hyatt Regency in ... impact functional foot orthotics, like Foot Levelers Stabilizing Orthotics, ... fasciitis, and hammertoes. , Invented by a chiropractor in ...
(Date:7/29/2014)... July 29, 2014 1WorldSync announces ... leading healthcare suppliers will utilize the Global Data ... information network to share product information with the ... trading partners across their global supply chain. Holger ... at B. Braun: "B. Braun serves customers in ...
Breaking Medicine News(10 mins):Health News:ProCare Protein Check Tests Surgical Instruments to Verify Effective Cleaning 2Health News:Determine patient preferences by means of conjoint analysis 2Health News:Determine patient preferences by means of conjoint analysis 3Health News:Determine patient preferences by means of conjoint analysis 4Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 2Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 3Health News:Bacardis make gift to significantly advance Mayo Clinic's regenerative medicine research 4Health News:Foot Levelers CEO Kent Greenawalt Speaking at FCA Convention 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 2Health News:B. Braun Selects 1WorldSync Unique Device Identification and Product Information Solution 3
... say the drug clodronate is an effective treatment for patients ... studied more than 1,000 patients // with breast cancer. Patients ... day or a placebo for five years. ,Results showed ... to their bones. Fifty-one of these patients were treated with ...
... identified a protein that essentially blocks HIV replication, in ... is not as effective at stopping HIV, say the ... of Nature. The team, headed by Joseph Sodroski, is ... Infectious Diseases (NIAID). ,"Identification of this HIV-blocking ...
... According to recent findings researchers say the risks and ... to be re-evaluated.// Researchers from Sweden studied more than ... of age. Participants had their intellectual capacity tested at ... school attendance records for the young men. ,Results ...
... pressure at home may lead to fewer blood pressure ... at patients’ homes to conventional doctors’ office measurements of ... patients with a diastolic blood pressure reading of 95 ... offices were included for the study. All of the ...
... a new treatment can now help chronic chest pain sufferers ... other antianginal medications it was found to improve the total ... ,Ranolazine is currently under review by the FDA. ... angina were randomly assigned to receive a placebo or one ...
... a non-surgical technique used to eliminate alternate pathways ... // Researchers now say that congestive heart failure ... of irregular heart rhythm experience significant improvement ... catheter ablation. ,58 patients with congestive heart ...
Cached Medicine News:
... The new Guidant VASOVIEW® ... to deliver a new level ... harvesting for both the saphenous ... simultaneous cut-and-seal capability, it lets ...
...
... Now rapid intrapartum or antepartum GBS results ... versus 2 days. This revolutionary in vitro diagnostic ... designed to be run in the clinical lab ... and delivery nurses 24 hours a day, ...
... contains primers and a FAM-labeled probe that is ... the mecA gene. In addition, this ASR contains ... an internal control sequence. This ASR requires an ... reporter dyes such as the Cepheid SmartCycler System. ...
Medicine Products: